Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Effecty vs Zappy Health

Two GLP-1 desks, one scoreboard. We put Effecty and Zappy Health head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 19 · Grade B

Effecty

Visit Effecty Full brief →
vs
No. 268 · Grade C

Zappy Health

Visit Zappy Health Full brief →

FDA warning letter, February 2026 — issued to Kare Solutions, LLC dba Zappy. See the FDA's warning letter database.

The verdict

Effecty takes this head-to-head.

Effecty scores 86 to 64 on our six-factor Brief Score — One of the few accredited desks pairing compounded pricing with brand-name access, nationwide.

That doesn't make Zappy Health a bad call — it's best for people wanting both compounded and brand-name glp-1 with flat pricing that doesn't rise with dose. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
85
48
Supply Reliability
87
65
Transparency
87
88
Access Breadth
90
80
Clinical Oversight
87
67
Track Record
82
36
EffectyBrief Score 86 · 64Zappy Health

Price, coverage & the tracker

EffectyZappy Health
Brief Score86/100 (B)64/100 (C)
Semaglutide$160/moFrom $159/mo (compounded)
Tirzepatide$240/moFrom $299/mo (compounded)
CoverageAll 50 states42 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Effecty: $160 sema / $240 tirz; LegitScript-certified with brand-name access nationwide.

Zappy Health: New to the tracker on 1 August 2026. The published line reads From $159/mo (compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole ranking at 94/100.

The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.